Executive Summary
NASA's $347.8M contract to Lockheed Martin for the Lucy mission to Jupiter Trojans signals strong, long-term commitment to deep-space exploration, providing LMT with revenue visibility through 2033 amid $223.5M already outlayed. This bullish award under NAICS 336414 highlights stability in space vehicle manufacturing but flags execution risks from the 16-year term and $476M subawards.
Investors should monitor option exercises to unlock full $396.5M potential.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior All NASA Contracts digest from February 26, 2026.
Investment Signals (1)
- Long-term NASA revenue lock-in for LMT (HIGH)▲
Lucy mission contract guarantees funding through 2033 with $347.8M obligated and potential $396.5M total.
Risk Flags (2)
- Execution [HIGH RISK]▼
16-year performance period to 2033-04-16 exposes funding continuity and project delays.
- Market [MEDIUM RISK]▼
$476M across 493 subawards creates subcontractor dependency.
Opportunities (2)
- ◆
Options uplift to $396.5M total value and recurring mission ops funding.
- ◆
$476M subawards ecosystem for supply chain expansion.
Sector Themes (1)
- ◆
Large cost-plus awards like Lucy underscore sustained U.S. investment in asteroid exploration via NAICS 336414.
Watch List (2)
- 👁
{"entity"=>"Lockheed Martin Corp", "reason"=>"Dominates single-record period with $347.8M NASA award; tracks revenue stability.", "trigger"=>"Q3 2026 earnings mention of Lucy outlays or options"}
- 👁
{"entity"=>"Lucy Mission Progress", "reason"=>"Key to 2033 revenue; $223.5M outlayed signals momentum.", "trigger"=>"NASA milestone delays or accelerations"}
Get daily alerts with 1 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: All NASA Contracts
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
US Pre-Market SEC Filings Roundup — May 26, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
Biotech Small-Cap Approvals — May 26, 2026
Biotech Small-Cap Approvals
May 26, 2026
Big Pharma Approvals — May 26, 2026
Big Pharma Approvals